Idioma:

A randomized, double‐blind trial of lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease

Bousvaros, Athos ; Guandalini, Stefano ; Baldassano, Robert N ; Botelho, Christine ; Evans, Jonathan ; Ferry, George D ; Goldin, Barry ; Hartigan, Lori ; Kugathasan, Subra ; Levy, Joseph ; Murray, Karen F ; Oliva‐Hemker, Maria ; Rosh, Joel R ; Tolia, Vasundhara ; Zholudev, Anna ; Vanderhoof, Jon A ; Hibberd, Patricia L

Inflammatory bowel diseases, 2005-09, Vol.11 (9), p.833-839 [Revista revisada por pares]

Philadelphia: Lippincott Williams & Wilkins, Inc

Texto completo disponible

Citas Citado por

Acciones

Título:
A randomized, double‐blind trial of lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease
Autor: Bousvaros, Athos ; Guandalini, Stefano ; Baldassano, Robert N ; Botelho, Christine ; Evans, Jonathan ; Ferry, George D ; Goldin, Barry ; Hartigan, Lori ; Kugathasan, Subra ; Levy, Joseph ; Murray, Karen F ; Oliva‐Hemker, Maria ; Rosh, Joel R ; Tolia, Vasundhara ; Zholudev, Anna ; Vanderhoof, Jon A ; Hibberd, Patricia L
Materias: Adolescent ; Adult ; Child ; Child, Preschool ; Crohn Disease - drug therapy ; Crohn's disease ; Double-Blind Method ; Female ; Humans ; inflammatory bowel disease ; Lactobacillus ; Lactobacillus rhamnosus ; Male ; Placebos ; probiotics ; Probiotics - therapeutic use ; Recurrence ; Time Factors ; Treatment Outcome
Es parte de: Inflammatory bowel diseases, 2005-09, Vol.11 (9), p.833-839
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-News-1
ObjectType-Feature-3
content type line 23
ObjectType-Feature-1
Descripción: Probiotics are widely used by patients with Crohn's disease (CD) in an attempt to improve their health, but few controlled studies have been done to evaluate the efficacy of these therapies. We conducted a randomized, placebo‐controlled trial of the probiotic Lactobacillus rhamnosus strain GG (LGG) to see if the addition of LGG to standard therapy prolonged remission in children with CD. Concomitant medications allowed in the study included aminosalicylates, 6‐mercaptopurine, azathioprine, and low‐dose alternate day corticosteroids. Seventy‐five children (age range, 5‐21 yr) with CD in remission were randomized to either LGG (n = 39) or placebo (n = 36) and followed for up to 2 years. The median time to relapse was 9.8 months in the LGG group and 11.0 months in the placebo group (P = 0.24); 31% (12/39) of patients in the LGG group developed a relapse compared with 6/36 (17%) of the placebo group (P = 0.18). The LGG was well tolerated, with a side effect profile comparable with placebo. This study suggests that LGG does not prolong time to relapse in children with CD when given as an adjunct to standard therapy.
Editor: Philadelphia: Lippincott Williams & Wilkins, Inc
Idioma: Inglés

Enlaces

View this record in MEDLINE/PubMed

Volver a la lista de resultados

Anterior Resultado 2 Siguiente Ir a la siguiente página

Realización: Logos de Redes Sociales:

A randomized, double‐blind trial of lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease

Philadelphia: Lippincott Williams & Wilkins, Inc

Buscando en bases de datos remotas, por favor espere